News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
Great news. CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm. See: https://www.cellcentric.com/press-release/cellcentric-secures-further-investment-from-brightedge/
Looking forward to IMS, end Sept. Inobrodib continuing to progress in clinical trials, treating R/R multiple myeloma and other haem malignancies. https://www.myelomasociety.org/events/20th-ims-annual-meeting/
Great to feature in @AmericanCancer, BrightEdge’s annual rpt: https://lnkd.in/eHimR4DR Aligned missions: addressing healthcare burden & inequity. Inobrodib, novel oral oncology drug, at home admin.
Great news. CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm. See: https://www.cellcentric.com/press-release/cellcentric-secures-further-investment-from-brightedge/
Looking forward to IMS, end Sept. Inobrodib continuing to progress in clinical trials, treating R/R multiple myeloma and other haem malignancies. https://www.myelomasociety.org/events/20th-ims-annual-meeting/
Great to feature in @AmericanCancer, BrightEdge’s annual rpt: https://lnkd.in/eHimR4DR Aligned missions: addressing healthcare burden & inequity. Inobrodib, novel oral oncology drug, at home admin.
A major step for our pioneering p300/CBP inhibitor, inobrodib. Making a difference to people with cancer. Many thanks to @endpts for covering our news: https://endpts.com/exclusive-pfizer-to-invest-25m-into-uk-biotech-cellcentric-with-epigenetics-approach-to-cancer/
A major milestone for our oral cancer drug, inobrodib. $25m strategic investment from @pfizer. See press release: https://www.cellcentric.com/press-release/cellcentric-announces-25m-strategic-investment-from-pfizer/
Our Chief Medical Officer comments on FDA Orphan Drug designation news. Helps speed up development/adoption treating multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-granted-fda-orphan-drug-designation-for-inobrodib-ccs1477-for-the-treatment-of-multiple-myeloma/
Great news. CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm. See: https://www.cellcentric.com/press-release/cellcentric-secures-further-investment-from-brightedge/
Looking forward to IMS, end Sept. Inobrodib continuing to progress in clinical trials, treating R/R multiple myeloma and other haem malignancies. https://www.myelomasociety.org/events/20th-ims-annual-meeting/
Great to feature in @AmericanCancer, BrightEdge’s annual rpt: https://lnkd.in/eHimR4DR Aligned missions: addressing healthcare burden & inequity. Inobrodib, novel oral oncology drug, at home admin.
A major step for our pioneering p300/CBP inhibitor, inobrodib. Making a difference to people with cancer. Many thanks to @endpts for covering our news: https://endpts.com/exclusive-pfizer-to-invest-25m-into-uk-biotech-cellcentric-with-epigenetics-approach-to-cancer/
A major milestone for our oral cancer drug, inobrodib. $25m strategic investment from @pfizer. See press release: https://www.cellcentric.com/press-release/cellcentric-announces-25m-strategic-investment-from-pfizer/
Our Chief Medical Officer comments on FDA Orphan Drug designation news. Helps speed up development/adoption treating multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-granted-fda-orphan-drug-designation-for-inobrodib-ccs1477-for-the-treatment-of-multiple-myeloma/
Great news. CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm. See: https://www.cellcentric.com/press-release/cellcentric-secures-further-investment-from-brightedge/
Looking forward to IMS, end Sept. Inobrodib continuing to progress in clinical trials, treating R/R multiple myeloma and other haem malignancies. https://www.myelomasociety.org/events/20th-ims-annual-meeting/
Great to feature in @AmericanCancer, BrightEdge’s annual rpt: https://lnkd.in/eHimR4DR Aligned missions: addressing healthcare burden & inequity. Inobrodib, novel oral oncology drug, at home admin.
A major step for our pioneering p300/CBP inhibitor, inobrodib. Making a difference to people with cancer. Many thanks to @endpts for covering our news: https://endpts.com/exclusive-pfizer-to-invest-25m-into-uk-biotech-cellcentric-with-epigenetics-approach-to-cancer/
A major milestone for our oral cancer drug, inobrodib. $25m strategic investment from @pfizer. See press release: https://www.cellcentric.com/press-release/cellcentric-announces-25m-strategic-investment-from-pfizer/
Our Chief Medical Officer comments on FDA Orphan Drug designation news. Helps speed up development/adoption treating multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-granted-fda-orphan-drug-designation-for-inobrodib-ccs1477-for-the-treatment-of-multiple-myeloma/
Latest press releases
